Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: johnlag who wrote (25917)	3/31/1999 4:12:00 PM
From: FrozenZ	Respond to of 122088

<imcl> My best guess is a merger with Merck. I doubt if it is the recent earnings report.

To: johnlag who wrote (25917)	3/31/1999 4:19:00 PM
From: HRAKA	Read Replies (1) \| Respond to of 122088

I think they're in some kinda conference this week. You know like to show their stuff off. (IMCL) Hraka

To: johnlag who wrote (25917)	3/31/1999 8:22:00 PM
From: Market Tracker	Respond to of 122088

<IMCL> Looks like Franklin Biotechnology Discovery Fund (FBDIX), had some nice things to say about IMCL this evening. cbs.marketwatch.com Another hopeful is ImClone Systems Inc. (IMCL). The company is scheduled to present data on treatment for head and neck cancer at American Society of Clinical Oncology conference in May. "When you add their drug to chemotherapy in head and neck cancer, the response rate is close to or above 90 percent," von Emster says. "These are patients in whom cancers grow regardless of how they've been treated. When the drug is added, all of sudden the cancer responds and dies or becomes significantly reduced," he says. There's also a group of patients in that study in which cancer went away, von Emster says. Meaning, possibly, that there are some jewels strewn about the minefield.